Annual report pursuant to Section 13 and 15(d)

Royalty Purchase Agreements - Bioasis (Details)

v3.20.4
Royalty Purchase Agreements - Bioasis (Details)
$ in Thousands
 12 Months Ended
Nov. 02, 2020
USD ($)
Feb. 25, 2019
USD ($)
agreement
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Agreements          
Payments to acquire milestones and royalties     $ 1,200 $ 19,300  
Contingent consideration under royalty purchase agreements     75 75  
Long-term royalty receivables     34,575 34,375 $ 15,000
Impairment of long-term royalty receivable     0 0  
Bioasis Technologies Inc | Royalty Purchase Agreement          
Agreements          
Percentage of option to purchase royalty right on future license agreements   1.00%      
Number of future license agreements under optional purchase right | agreement   2      
Obligation upon exercise of options per licensed product, second agreement   $ 300      
Obligation upon exercise of options per licensed product, third agreement   400      
Payments to acquire milestones and royalties   300      
Contingent consideration under royalty purchase agreements   100 100    
Potential future cash payments   200      
Long-term royalty receivables   $ 400      
Changes in estimated fair value of contingent consideration     0 $ 0  
Payments of contingent consideration     0    
Impairment of long-term royalty receivable     0    
Bioasis Technologies Inc | Second Royalty Purchase Agreement          
Agreements          
Payments to acquire milestones and royalties $ 1,200        
Long-term royalty receivables $ 1,200        
Impairment of long-term royalty receivable     $ 0